
==== Front
J Endocrinol Invest
J Endocrinol Invest
Journal of Endocrinological Investigation
0391-4097
1720-8386
Springer International Publishing Cham

38503992
2356
10.1007/s40618-024-02356-9
Review
Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis
http://orcid.org/0000-0001-7550-7023
Bioletto F. fabio.bioletto@unito.it

Sibilla M.
Gasco V.
Ghigo E.
Grottoli S.
https://ror.org/048tbm396 grid.7605.4 0000 0001 2336 6580 Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin, 10126 Italy
19 3 2024
19 3 2024
2024
47 9 21432155
28 12 2023
3 3 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Patients with non-functioning pituitary adenoma (NFPA) often present with a variety of clinical manifestations and comorbidities, mainly determined by the local mass effect of the tumor and by hypopituitarism. Whether this has an impact on overall mortality, however, is still unclear.

Methods

PubMed/Medline, EMBASE, and Cochrane Library databases were systematically searched until May 2023 for studies reporting data either about standardized mortality ratios (SMRs) or about predictors of mortality in patients with NFPA. Effect sizes were pooled through a random-effect model. This systematic review and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO, #CRD42023417782).

Results

Eleven studies were eligible for inclusion in the systematic review; among these, five studies reported data on SMRs, with a total follow-up time of approximately 130,000 person-years. Patients with NFPA showed an increased mortality risk compared to the general population (SMR = 1.57 [95%CI: 1.20–1.99], p < 0.01). Age and sex appeared to act as effect modifiers, with a trend towards higher SMRs in females (SMR = 1.57 [95%CI: 0.91–2.41], p = 0.10) than in males (SMR = 1.00 [95%CI: 0.89–1.11], p = 0.97), and in patients diagnosed at age 40 years or younger (SMR = 3.19 [95%CI: 2.50–3.97], p < 0.01) compared to those with later onset of the disease (SMR = 1.26 [95%CI: 0.93–1.65], p = 0.13). The trend towards excess mortality was similar in patients with normal (SMR = 1.22 [95%CI: 0.94–1.53], p = 0.13) or deficient (SMR = 1.26 [95%CI: 0.82–1.79], p = 0.27) pituitary function.

Conclusions

Excess mortality is observed in patients with NFPA, regardless of pituitary function, especially in women and in patients with a younger age at diagnosis.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-024-02356-9.

Keywords

Non-functioning pituitary adenoma
NFPA
Standardized mortality ratio
SMR
Hypopituitarism
Università degli Studi di TorinoOpen access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement.

issue-copyright-statement© Italian Society of Endocrinology (SIE) 2024
==== Body
pmcIntroduction

Non-functioning pituitary adenomas (NFPAs) are relatively common neoplasms arising from the adenohypophyseal cells [1], not associated with clinical or biochemical evidence of pituitary hormone hypersecretion [2]. NFPAs represent approximately 30% of all pituitary adenomas [3–5], with a yearly incidence of around 10 cases per million and a prevalence of 70–140 cases per million inhabitants [3, 5, 6].

Most of these tumors exhibit a benign behavior [1, 2, 7] and may be typically cured or controlled by surgery, radiotherapy, or even surveillance alone [8–11]. Nonetheless, they are frequently associated with various clinical manifestations and comorbidities, essentially determined by the local mass effect of the tumor on the surrounding tissues (e.g., headache, visual field defects, etc.) and to hypopituitarism [2, 9, 12]. Treatments for NFPAs might sometimes contribute to the onset of comorbidities [9], and patients treated for NFPA are overall characterized by an impaired quality of life [13].

Whether NFPAs are associated with an increased mortality compared with the general population is still a matter of debate. Studies assessing the long-term mortality outcomes of patients with NFPA are limited and provide conflicting results [14–19].

Given that patients with NFPA frequently have pituitary insufficiency at least to some degree, and that hypopituitarism of various etiologies is associated with increased mortality [20], a slightly increased mortality risk in patients with NFPA might be expected. However, this inference is not straightforward, as most studies demonstrating an increased mortality in patients with hypopituitarism were based on heterogeneous groups of patients with different underlying causes of hypopituitarism (e.g., functioning pituitary adenomas, craniopharyngiomas, etc.), having the potential to affect mortality regardless of pituitary hormone deficiencies [20–24]. Conversely, a slight mortality excess in NFPA patients with intact pituitary function cannot be excluded a priori, as some recent studies seem to point out [14, 15].

Other possible factors may also predict or account for mortality in patients with NFPA. Excess mortality has been shown to be higher in women than in men with pituitary disease [25], likely due to the fact that pituitary dysfunction jeopardizes the natural survival advantage that women have compared to men in the general population [25, 26]. However, it is still unclear whether this sexual dimorphism might be present also when focusing the analysis on patients with NFPA. Older age at diagnosis has been shown as an independent predictor of mortality in some series [14, 19, 27], although other studies suggest that, compared to the general population, excess mortality might be higher in younger patients [15, 16]. Radiotherapy (RT) may also contribute to an increased risk of premature death, mainly due to a higher incidence of cerebrovascular events [28].

Given this complex picture, the aim of this systematic review and meta-analysis was to evaluate all published data about mortality in patients with NFPA compared to the general population, as well as its possible independent predictors, in order to provide an up-to-date synthesis of the current knowledge in this regard.

Methods

Search strategy and study selection

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [29]. The process of literature search and study selection was made by two independent reviewers (F.B., M.S.); all disparities were resolved through consensus. The following electronic databases were queried until May 6th 2023: PubMed/Medline, EMBASE, and Cochrane Library. The search strategy was performed using a combination of relevant database-specific search terms to identify studies evaluating mortality in patients with NFPA. The full search strategy is presented in the Supplementary Material (Appendix 1). No filters were applied for study design, language, and publication date. After duplicate removal, all studies found with the aforementioned search were evaluated for inclusion in the meta-analysis, first by title/abstract screening and then by full-text review. We excluded studies from our analysis according to the following exclusion criteria: (a) conference abstracts; (b) case reports or case series; (c) unavailability of any of the primary outcomes of interest, as defined in the following subsection. Study restricted to selected subgroups of patients with NFPA based on specific comorbidities or associated conditions (e.g., only patients with central adrenal insufficiency, only patients with GH deficiency, etc.) were not systematically searched and were excluded from the analysis. In case of patient overlap between two studies, the one with the largest patient cohort was considered; however, studies excluded from the main analysis for this reason could be still eligible for inclusion in subgroup analyses if they reported additional data that were not available in the main report. This systematic review and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO, #CRD42023417782).

Outcomes

The primary outcomes of interest were: (i) the evaluation of standardized mortality ratio (SMR) in patients with NFPA; (ii) the evaluation of possible predictors of mortality in patients with NFPA. With respect to the first endpoint, stratified data according to sex, age at diagnosis (less or greater than 40 years old), and residual pituitary function were also collected, when provided.

Data extraction

Two authors (F.B., M.S.) independently examined and extracted data from papers which met the inclusion criteria using pre-specified data extraction templates. For each eligible study, the following information were collected: (a) first author and publication year; (b) study design; (c) patient selection criteria; (d) number of subjects enrolled; (e) patients’ characteristics in terms of demographic data; (f) SMR in the whole NFPA cohort; (g) SMR in NFPA subgroups according to sex, age at diagnosis, and presence/absence of hypopituitarism; (h) internal predictors of mortality within study cohorts at survival analyses.

Study quality and risk of bias assessment

The risk of bias was independently assessed for each included study by two authors (F.B., M.S.), according to the criteria described by Newcastle–Ottawa Scale [30]. This scale evaluates studies according to eight items belonging to three domains: selection (four items), comparability (one item) and outcome (three items). Each study can be awarded a maximum of one point for each item with the selection and outcome domains, and a maximum of two points for the item in the comparability domain. The overall quality of the studies is therefore evaluated on a 9-point scale, with scores of at least 5 being considered as indices of good quality.

Statistical analysis

The SMR was chosen as the principal measure of outcome, computed by dividing the number of observed deaths by the number of expected deaths in a hypothetical cohort extracted from the general population and matched by age and sex to the patient group. The standard error (SE) of the SMR was calculated using the method by Vandenbroucke [31]. A random-effect model was adopted for the statistical pooling of data. Higgins I2 statistics and Cochran Q test were used to assess heterogeneity between studies. Small-study effects were evaluated by visual assessment of funnel plot asymmetry. A cut-off of 0.05 was adopted for the definition of statistical significance. Statistical analysis was performed using STATA 17 (StataCorp, College Station, Texas, USA).

Results

Search results and characteristics of the included studies

A total of 622 records were identified in the initial literature search. Removal of duplicates led to an overall pool of 469 studies. An accurate title or abstract revision was sufficient to exclude 445 articles as not pertinent or not fulfilling our prespecified inclusion or exclusion criteria. The remaining 24 studies were assessed in full-text for eligibility; among these, 11 studies [14–19, 27, 32–35] met all criteria for being included in the final analysis (Fig. 1). Five studies [14–18] reported relevant data about the first outcome of interest (i.e., the evaluation of SMR in patients with NFPA), encompassing 23,123 patients with NFPA with a total follow-up time of approximately 130,000 person-years; one further study [32] reported data stratified by sex relative to the cohort of patients of one of the previous five [17]. Seven studies [14, 16, 19, 27, 33–35] reported relevant data about the second outcome of interest (i.e., the evaluation of predictors of mortality in patients with NFPA at internal analyses); two of them [34, 35] analyzed a subset of patients of a larger cohort [16], but were included in the qualitative synthesis of results because additional analyses of internal predictors were performed.Fig. 1 Flow-chart of study inclusion. Abbreviations: NFPA, non-functioning pituitary adenoma

Table 1 summarizes the main study characteristics. All of them had a retrospective design. Three were single center studies [14, 18, 19], 3 were multicenter studies [17, 32, 33], and 5 were population-based studies [15, 16, 27, 34, 35]. In 4 studies [15, 16, 34, 35], the patient group was represented by patients treated or followed for NFPA, identified through the records of regional or national patient registries; in the other 7 studies [14, 17–19, 27, 32, 33], the patient group was represented only by patients who received active treatment for NFPA.Table 1 Study characteristics. Abbreviations: HIRA-RID, health insurance review and assessment—rare intractable disease; N, number; NA, not available; NFPA, non-functioning pituitary adenoma; NHIRD, national health insurance research database; SMR, standardized mortality ratio

First author,
year	Study design	Selection criteria of NFPA patients	N of subjects	Mean/ median follow-up (years)	Sex distribution
(% male)	Mean/ median age
(years)	Patients who received active treatment
(%)	Patients with hypopituitarism (%)	Reporting SMR	Reporting internal analyses of predictors of mortality	
Chang,

2008 [19]

	Single center	Patients treated for NFPA	663	14.0	59	53.0	100	NA	Noa	Yes	
Dekkers,

2007 [18]

	Single center	Patients treated for NFPA	174	9.1	56	55.3	100	91	Yes	No	
Hammarstrand,

2017 [35]

	Population-based	Patients with NFPA (followed in the western region of Sweden)	392	12.7	64	58.7	74	80	Yesb	Yes	
Hsiao,

2019 [27]

	Population-based	Patients treated for NFPA (registered in the Taiwan NHIRD database)	548	3.4c	58	43.4c	100	NA	No	Yes	
Lindholm,

2006 [33]

	Multicenter	Patients treated for NFPA	160	12.4	57	55.1c	100	70	Yesd	No	
Nielsen,

2007 [17]

	Multicenter	Patients treated for NFPA	192	10.8c	60	54.5c	100	73	Yes	No	
Ntali,

2016 [14]

	Single center	Patients treated for NFPA	546	8.0	61	58.7	100	NA	Yes	Yes	
Oh,

2021 [15]

	Population-based	Patients with NFPA (registered in HIRA-RID database)	19,416	5.3e	44	51.0	NA	21	Yes	No	
Olsson,

2015 [16]

	Population-based	Patients with NFPA (registered in the Swedish National Patients Registry)	2795	7.0	54	58.4	53	54	Yes	Yes	
Olsson,

2017 [36]

	Population-based	Patients with NFPA (followed in the western region of Sweden)	426	10.1c	64c	60.9c	72	NA	Yesf	Yes	
O’Reilly,

2016 [34]

	Multicenter	Patients treated for NFPA	519	7.0	62	57.0	100	83	No	Yes	
a SMR was reported to be significantly increased, but quantitative data were not specified

b SMR data were not included in the meta-analysis because the patient cohort represented a subset of the one analysed by Olsson et al. (2015) [16]; however, this study was included in the evaluation of internal predictors of mortality, as it provided further relevant data compared to the study by Olsson et al. (2015) [16]

c Pooled estimate

d SMR data were not included in the main meta-analysis because the patient cohort represents a subset of the one analysed by Nielsen et al. (2007) [17]; however, this study was quantitatively included in subgroup analyses, as it provided additional relevant data stratified by presence/absence of hypopituitarism

e Median follow-up in the whole cohort of patients with pituitary adenomas (functioning and non-functioning)

f SMR data were not included in the meta-analysis because the patient cohort represented a subset of the one analysed by Olsson et al. (2015) [16]; however, this study was included in the evaluation of internal predictors of mortality, as it provided further relevant data compared to the study by Olsson et al. (2015) [16]

Evaluation of standardized mortality ratio

Five studies [14–18] evaluating SMR in patients with NFPA fulfilled the pre-specified eligibility criteria. Overall, the SMR of patients with NFPA was significantly increased compared to the general population (SMR = 1.57 [95%CI: 1.20–1.99], p < 0.01), with a significant between-study heterogeneity (I2  =  95.26%, p < 0.01) (Fig. 2). One of these studies [14] was an outlier, with a SMR = 3.60 [95%CI: 2.90–4.50]. Even excluding this study in a sensitivity analysis, however, the pooled SMR remained significantly increased, though to a lesser extent (SMR = 1.27 [95%CI: 1.01–1.55], p = 0.04) (Fig. 2).Fig. 2 Mortality in NFPA compared to the general population, evaluated by SMR. The lower panel presents a sensitivity analysis after the exclusion of an outlier [14]. Abbreviations: CI, confidence interval; NFPA, non-functioning pituitary adenoma; SMR, standardized mortality ratio

Three pre-specified subgroups analyses were performed by stratifying the SMR according to sex, age at diagnosis (less or greater than 40 years old) and to the presence/absence of hypopituitarism. Overall, two studies [16, 17] reported relevant data for the first subgroup analysis, two studies [15, 16] reported relevant data for the second subgroup analysis, and three studies [15, 16, 32] reported relevant data for the third one. Of note, one [32] of these three latter studies was not included in the main meta-analysis, because the patient cohort represented a subset of the one analysed by Nielsen et al. [17]; however, this study was quantitatively included in subgroup analyses, as it provided additional relevant data stratified by presence/absence of hypopituitarism.

Although limited by the small number of studies, the first subgroup analysis showed a possible higher mortality risk in women (SMR = 1.57 [95%CI: 0.91–2.41], p = 0.10) than in men (SMR = 1.00 [95%CI: 0.89–1.11], p = 0.97), though without reaching statistical significance in either subgroup (Fig. 3). Of note, the SMR in females was significantly increased in each of the two studies considered alone, with only a borderline-significant trend being maintained when pooling the data, as a consequence of the use of a random-effects model in a context of few studies with high between-study heterogeneity.Fig. 3 Mortality in NFPA compared to the general population, evaluated by SMR, stratified by sex. Abbreviations: CI, confidence interval; NFPA, non-functioning pituitary adenoma; SMR, standardized mortality ratio

In the second subgroup analysis, the SMR was higher in patients diagnosed at less than 40 years of age (SMR = 3.19 [95%CI: 2.50–3.97], p < 0.01), than in those diagnosed afterwards (SMR = 1.26 [95%CI: 0.93–1.65], p = 0.13) (Fig. 4).Fig. 4 Mortality in NFPA compared to the general population, evaluated by SMR, stratified by age at diagnosis. Abbreviations: CI, confidence interval; NFPA, non-functioning pituitary adenoma; SMR, standardized mortality ratio

In the third subgroup analysis, the SMR was similar between patients with normal (SMR = 1.22 [95%CI: 0.94–1.53], p = 0.13) and deficient (SMR = 1.26 [95%CI: 0.82–1.79], p = 0.27) pituitary function, with a non-significant trend towards higher mortality in both subgroups (Fig. 5). Of note in this third analysis, it was not possible to quantitatively include the data from the study by Ntali et al. [14], as no specific stratification of results according to the presence or absence of hypopituitarism is provided; however, the authors provide a stratified analysis of SMRs according to the functional status of each single pituitary axis, finding an increase in mortality which was independent of their normal or deficient functioning. The inclusion of the results of this study, therefore, would have likely better supported the findings of an increased mortality in both subgroups.Fig. 5 Mortality in NFPA compared to the general population, evaluated by SMR, stratified by pituitary function. Abbreviations: CI, confidence interval; NFPA, non-functioning pituitary adenoma; SMR, standardized mortality ratio

Evaluation of predictors of mortality at internal analyses

Seven studies [14, 16, 19, 27, 33–35] evaluated, within patients with NFPA, the possible role of various factors in the prediction of mortality. Any predictor evaluated in univariate or multivariable/adjusted survival analyses was considered and reported (Table 2). The results were characterized by an overall heterogeneity between studies, both in terms of the predictors that have been evaluated and of the quantitative findings that have been observed (Table 2).Table 2 Predictors of mortality at internal analyses. Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CCI, Charlson comorbidity index; CI, confidence interval; F, female; GHD, GH deficiency; GHRT, GH replacement therapy; GTR, gross-total resection; HCeq, hydrocortisone equivalent dose; HR, hazard ratio; LT4, levothyroxine; M, male; STR, subtotal resection

First author, year	Univariate analyses	Multivariable/adjusted analyses	
Non-significant predictors	Significant predictors	HR (95%CI)	Non-significant predictors	Significant predictors	HR (95%CI)	
Chang,

2008 [19]

	Local extension

Histopathological subtype

	Age

Size > 25 mm

Male sex

STR

Radiotherapy

	1.09 (1.08–1.17)

1.37 (1.05–1.79)

1.61 (1.25–2.08)

1.27 (1.01–1.62)

1.29 (1.00–1.67)

	–	Age at diagnosis

GTR and no radiotherapy

	1.09 (1.08–1.84)

0.72 (0.54–0.94)

	
Hammarstrand,

2017 [35]

	–	–	–	Sexa

Radiotherapya

	HCeq > 20 mg/daya	1.88 (1.06–3.33)	
Hsiao,

2019 [27]

	–	–	–	Transphenoidal surgeryb

Sex

Income

Region of residence

ASA scores

	Stereotactic radiosurgeryb

Age at diagnosis

Charlson comorbidity index

	0.36 (0.15–0.85)

See notec

See noted

	
Ntali,

2016 [14]

	Sex

Presentation with apoplexy

Cavernous sinus invasion

Extent of surgical removal

Repeat surgery for relapse

Untreated hypogonadism

ACTH deficiency

TSH deficiency

Diabetes insipidus

	Age at diagnosis

Radiotherapy

Tumor regrowth

Untreated GHD

	(1.08–1.13)

2.21 (1.31–3.73)

1.99 (1.11–3.56)

0.32 (0.16–0.64)

	Radiotherapy

Tumor regrowth

Untreated GHD

	Age at diagnosis	1.10 (1.07–1.13)	
Olsson,

2015 [16]

	–	–	–	Model 1

Hypopituitarism

Diabetes insipidus

	Age at diagnosis

Diagnosed at ≤ 40 years

	M: 1.12 (1.10–1.13)

F: 1.13 (1.11–1.15)

M: 3.47 (1.28–9.42)

F: 4.20 (1.32–13.32)

	
Model 2

–

	Age at diagnosis

Radiotherapy

	M: 1.11 (1.09–1.12)

F: 1.12 (1.10–1.14)

M: 1.99 (1.15–3.42)

F: 2.81 (1.63–4.83)

	
Olsson,

2017 [36]

	–	–	–	Radiotherapy

BMI

Sex

Ongoing replacement therapies (other than GHRT)

	Age at diagnosis

Years of GHRT

	1.10 (1.08–1.12)

0.94 (0.91–0.98)

	
O’Reilly,

2016 [34]

	–	–	–	GHDf

TSH deficiencyf

Diabetes insipidusf

Gonadal replacement therapyg

	Radiotherapye

Hypogonadismf

ACTH deficiencyf

HCeq ≥ 30 mg/dayf

LT4 < 100 µg/dayf

Untreated GHDf

	1.62 (1.01–2.60)

2.56 (1.10–5.96)

2.26 (1.15–4.47)

3.79 (1.49–9.67)

2.41 (1.23–4.73)

5.81 (0.73–46.23)h

	
a The model was also adjusted for age, but no data was reported about the possible relationship between age and mortality

b Compared to fractionated radiotherapy

c Age was divided into 8 categories, with progressively increasing HR

d Reference: CCI = 0; HR = 2.08 (1.33–3.26) for CCI = 1–2; HR = 4.56 (2.51–7.28) for CCI ≥ 3

e Internal Cox adjusted for age at diagnosis, attained age, sex and surgery

f Internal Cox adjusted for age at diagnosis, attained age, sex, surgery and radiotherapy

g Internal Cox stratified by sex and adjusted for age at diagnosis, attained age, surgery and radiotherapy

h This result is presented and discussed by the Authors as statistically significant (p = 0.04), although the reported 95%CI contains 1

When focusing on multivariable/adjusted analyses, age at diagnosis was found to be a positive predictor of mortality in four studies [14, 16, 19, 35], although in one of them [16] an independent increase in mortality risk was also observed in patients diagnosed at younger age (≤ 40 years). RT was independently associated with mortality in three studies [16, 19, 33], while no significant association was found in three others [14, 34, 35]; of note, in the study by Hsiao et al. [27], patients treated with stereotactic radiosurgery showed a lower risk of death as compared to those treated with fractionated RT. With regard to pituitary function, the findings varied between the different studies; hypopituitarism was not found to be a significant predictor of mortality neither by Ntali [14] nor by Olsson [16]; only in one study, by O’Reilly et al. [33], a significant association between some pituitary axis deficiencies (i.e., gonadotropin and ACTH deficiency) and mortality was found. Of note, in the same study [33], increased hydrocortisone doses (≥ 30 mg/day), lower levothyroxine doses (< 100 µg/day) and untreated GHD were associated with an increased risk of death. The finding of an increased mortality in patients replaced with higher glucocorticoid doses was also confirmed by Hammarstrand et al. [34]. The observation of a longer survival in patients on GH replacement therapy compared to those not treated with recombinant human GH (rhGH) was also made by Olsson et al. [35].

Quality assessment and evaluation of small-study effects

The results of the quality assessment of the studies are reported in Supplementary Table 1 and 2. Altogether, the risk of bias appeared to be moderate-to-low in all studies. Visual assessment of funnel plot asymmetry revealed the possible presence of small-study effects due to the presence of an outlier (Supplementary Fig. 1); the potential impact of this on the results has already been addressed by specific sensitivity analysis.

Discussion

This systematic review and meta-analysis showed that patients with NFPA have an increased risk of mortality compared to the general population. The pooled SMR was 1.57 (95%CI: 1.20–1.99) and remained significantly increased in a sensitivity analysis even after the exclusion of an outlier [14].

To the best of our knowledge, no previous meta-analyses had specifically evaluated mortality rates in patients with NFPA compared to the general population. The studies published to date reported heterogeneous results, showing either an increased [14, 15], borderline significant [16], or even normal rate of mortality [17, 18]. In the present meta-analysis, the statistical pooling of all published data shows that an increase in all-cause mortality in patients with NFPA is indeed present. Notably, this conclusion is further supported by the findings of a sixth study, by Chang et al. [19], which also reported a statistically significant increase in SMR for patients with NFPA, but could not be quantitatively pooled with the others because numerical data were not reported by the authors.

By definition, NFPAs are not associated with pituitary hormone hypersecretion [2], and are mostly benign in behaviour [1, 2, 7]. Nonetheless, they are frequently associated with relevant clinical manifestations due to the local mass effect of the tumor (e.g., headache, visual field defects) and/or to the effects of hypopituitarism [2, 9, 12]. Treatments for NFPAs might also contribute to the onset of comorbidities [9] and to an impairment in quality of life [13]. Whether this had an impact on overall mortality, however, was still unclear.

In the present study, we conducted three separate subgroup analyses, stratifying SMR according to sex, age at diagnosis, and presence or absence of hypopituitarism. The results of these analyses were limited by the small number of studies available, which made them likely underpowered, but their interpretation is still meaningful if properly taking this limitation into account.

Two studies [16, 17] examined separately the SMRs in males and females; in both cases, mortality was found to be significantly increased in women, while no excess mortality was observed in men. When pooling these data, the statistical significance of the increase in female mortality was formally lost, with only a borderline-significant trend being maintained, as a consequence of the use of a random-effect model in a context characterized by few studies with high between-study heterogeneity. However, based on the available data, it is reasonable to think that sex may indeed play a role as an effect modifier in this context, with excess mortality predominantly (if not uniquely) affecting females rather than males. This finding is not surprising, as an excess mortality in women has been already showed in other contexts of pituitary disease [25, 26]. The main hypothesis to justify this is that women with pituitary disease lose their natural survival advantage over men. Another possible explanation might be an underdiagnosis of hypopituitarism in women, since many of the diagnostic tests are not gender specific, with consequent undertreatment [25, 26]. Different effects of hormonal insufficiency and of replacement therapy between men and women are other factors that may also play a role [20, 25, 26].

When evaluating the role of age, two studies [15, 16] reported stratified SMRs data according to age at diagnosis; in both cases, a more marked increase in SMR was observed for patients diagnosed with NFPA at 40 years or younger, while excess mortality was less marked in patients older than that age. Notably, at internal analyses, older age was conversely found to be positively associated to mortality in few studies [14, 19, 27]. These two findings, however, are not necessarily in contrast; in fact, SMRs evaluates excess mortality compared to the general population, while internal analyses evaluate overall mortality within the cohort of NFPA patients. Not surprisingly, age acts as a positive predictor of overall mortality at internal analyses, as it does across the spectrum of most diseases. Conversely, when assessing excess mortality, younger patients exhibit the most evident disadvantage compared to the age- and sex-matched general population. Thus, similarly to sex, also age seems to act as an effect modifier, with excess mortality predominantly affecting younger patients rather than older ones.

When focusing on pituitary dysfunction, we found similar SMRs in patients with intact or deficient pituitary function, with a borderline-significant trend towards a higher mortality in both subgroups. At internal analyses, hypopituitarism was not found to be a significant predictor of mortality neither by Ntali [14] nor by Olsson [16]; only in the study by O’Reilly et al. [33] a significant association between some pituitary axis deficiencies (i.e., gonadotropin and ACTH deficiency) and mortality was found.

In previous studies, conducted in broader settings of patients with different pituitary diseases, hypopituitarism of various etiologies was shown to be associated with an increased mortality risk [20]. Inadequate hormonal replacement therapy has been proposed as a possible explanation of excess mortality [24, 26, 33, 36–38]. Replacement therapies have evolved and developed in the past decades, with the aim of being as close to normal physiology as possible, mimicking circadian rhythm and trying to avoid under/over treatment [39, 40]. Their impact on mortality in the setting of patients with NFPA has been investigated in some studies, as previously outlined. The available data suggest that GH replacement therapy is a safe option in patients with NFPA, with no evidence of increased mortality in treated patients. In the studies by Olsson et al. [35] and by O’Reilly et al. [33], treatment with rhGH was found to be associated with lower mortality; however, the observational nature of these finding makes it impossible to conclude towards a causal relationship. The finding of an association between a low LT4 replacement dose and mortality has been suggested as an isolate finding by O’Reilly et al. [33]; the interpretation of this result, however, is unclear; LT4 requirements are dependent on body weight, but this point was not accounted for in the analysis; moreover, monitoring parameters of under- or over-replacement (i.e., serum fT4 and fT3 values) were not reported; therefore, it is not possible to conclude whether the observed relationship between low replacement doses of LT4 and mortality was due to true under-replacement or to some unadjusted confounding. The relationship between higher doses of glucocorticoid replacement therapy and increased mortality is more consistent. Two studies [33, 34] examined the relationship between glucocorticoid replacement dose and mortality, and in both cases a significant association between higher doses and an increased risk of death was observed. This is in line with findings in other contexts [36, 37, 41], in which higher glucocorticoid replacement doses were associated with an adverse cardiometabolic profile, and with a consequent increase in morbidity and mortality. Nevertheless, it should be noted that this association does not necessarily imply a causal relationship, as the available evidence is observational in nature and, thus, selection bias or other systematic errors cannot be completely ruled out.

Based on the available evidence, a slight mortality excess also in NFPA patients with apparently preserved pituitary function cannot be excluded. As previously outlined, we did not find consistent evidence supporting a difference in excess mortality in patients with NFPA with or without hypopituitarism, except possibly in case of inadequate hormonal replacement therapies. Notably, in the study by Oh et al. [15], which is the largest currently available, patients with normal pituitary function were found to have a significantly increased mortality. In the study by Olsson et al. [16], a slight borderline-significant increase in mortality was also found. Ntali et al. [14] did not report data based on preserved or deficient pituitary function as a whole, but they evaluated deficits in each single axis individually and, interestingly, an increased mortality was found also in patients with intact tropin secretions.

The reason behind these results is not clear. In some cases, health consequences due to local mass effect and/or to the treatments received might contribute to mortality regardless of their effect on pituitary function [2, 8]. In other cases, an underdiagnosis of hypopituitarism might be hypothesized. For instance, patients that are not candidate for GH replacement therapy might not be tested for GHD, which may thus remain undiagnosed in some cases [42, 43]. More in general, however, it cannot be excluded that NFPA patients with apparently preserved pituitary function may harbor subclinical alterations in the mechanisms of control of pituitary secretion compared to a completely healthy hypophysis, which do not get detected by the commonly used diagnostic work-up. In fact, the diagnosis of hypopituitarism essentially relies on standardized tests and reference values, taking little account of individual hormonal setpoints [26, 44] and potentially leading to an under-recognition of milder functional derangements. To give an example, although the general population may exhibit a wider spectrum of TSH and fT4 values, individual TSH/fT4 levels tend to remain relatively stable over time [26, 45]; consequently, patients having their natural “thyrostat” set to mid-high fT4 levels might still maintain fT4 levels within the normal range even when a mild damage of their hypothalamus–pituitary–thyroid axis is present [26]; similar arguments can also be made with regard to other axes, and underline the limitations of current diagnostic tools for hypopituitarism. Clearly, even accepting the hypothesis that some alterations of pituitary secretion might in part go undiagnosed using standard references, the clinical implications are still unclear; on the one hand, it might be argued that only milder derangements are missed by standard diagnostic tests; however, though being mild, they remain untreated, and this might still determine a slight excess in mortality when large cohorts are analyzed. Nevertheless, further studies are needed to analyze this aspect and its possible clinical significance.

With regard to treatments, in particular, the role of RT as an independent predictor of mortality has been investigated by several authors. Among the studies included in this systematic review, RT was associated with mortality in three of them [16, 19, 33], while three others [14, 34, 35] found no differences between irradiated and non-irradiated patients. Of note, among irradiated patients, possible differences between different RT protocols (i.e., radiosurgery vs fractionated RT) might be present [27]. RT-induced hypopituitarism is a relatively frequent consequence of RT [26] and can at least in part explain an excess in morbidity and mortality in irradiated patients; nevertheless, a direct detrimental effect of RT can also be present, mainly due to a higher incidence of cerebrovascular events [28].

Our analysis had some limitations. Firstly, the strength of the conclusions was limited by the low number of available studies; this was particularly true for the subgroup analyses, which were likely underpowered to properly evaluate possible differences in the assessment of the outcome. Secondly, the quality was limited by that of the included studies; nevertheless, according to the Newcastle–Ottawa scale, the risk of bias was generally moderate-to-low, which reassured about the likely small impact of this issue on the final results. Thirdly, patients’ inclusion criteria were partly different between studies, and this could be responsible for a certain degree of heterogeneity in the reported results; however, heterogeneity is a common limitation of all meta-analyses, and appropriate statistical methods – such as the use of a random-effect model – were adopted to account for it. Fourthly, the available evidence comes from patients treated for NFPA or registered for NFPA in national disease registries; therefore, it is essentially representative of lesions considered to be of actual or potential clinical relevance. Consequently, the results obtained should not be generalized to patients with small non-functioning microadenomas, which usually do not cause any signs or symptoms, are often discovered incidentally, do not need any active treatment in the majority of cases, and are most likely completely benign entities with no impact on life expectancy, morbidity or quality of life.

In conclusion, our study was the first meta-analysis evaluating the impact of NFPAs on mortality. A slight excess in mortality could be observed, and was more evident for women and for younger patients (< 40 years old). On the other hand, patients with intact or deficient pituitary function had comparable SMRs, with a non-significant trend towards higher mortality in both subgroups.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 80 KB)

Acknowledgements

The authors would like to thank Dr. Daniela Cuboni, Dr. Luigi Simone Aversa, Dr. Emanuele Varaldo, Dr. Alessandro Maria Berton and Dr. Nunzia Prencipe for their valuable advice.

Funding

Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. This research did not receive any specific grant.

Data availability

Not applicable.

Code availability

Not applicable.

Declarations

Conflict of interest

Silvia Grottoli is member of the Editorial Board of the Journal of Endocrinological Investigation. The other authors have no competing interests to declare.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Asa SL Mete O Perry A Osamura RY Overview of the 2022 who classification of pituitary tumors Endocr Pathol 2022 33 6 26 10.1007/s12022-022-09703-7 35291028
Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 who classification of pituitary tumors. Endocr Pathol 33:6–26. 10.1007/s12022-022-09703-735291028 10.1007/s12022-022-09703-7
2. Greenman Y Stern N Non-functioning pituitary adenomas Best Pract Res Clin Endocrinol Metab 2009 23 625 638 10.1016/j.beem.2009.05.005 19945027
Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:625–638. 10.1016/j.beem.2009.05.00519945027 10.1016/j.beem.2009.05.005
3. Daly AF Rixhon M Adam C High prevalence of pituitary adenomas: a cross-sectional study in the province of liège, belgium J Clin Endocrinol Metab 2006 91 4769 4775 10.1210/jc.2006-1668 16968795
Daly AF, Rixhon M, Adam C et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of liège, belgium. J Clin Endocrinol Metab 91:4769–4775. 10.1210/jc.2006-166816968795 10.1210/jc.2006-1668
4. Fernandez A Karavitaki N Wass JAH Prevalence of pituitary adenomas: a community-based, cross-sectional study in banbury (oxfordshire, UK) Clin Endocrinol (Oxf) 2010 72 377 382 10.1111/j.1365-2265.2009.03667.x 19650784
Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in banbury (oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. 10.1111/j.1365-2265.2009.03667.x19650784 10.1111/j.1365-2265.2009.03667.x
5. Raappana A Koivukangas J Ebeling T Pirilä T Incidence of pituitary adenomas in northern finland in 1992–2007 J Clin Endocrinol Metab 2010 95 4268 4275 10.1210/JC.2010-0537 20534753
Raappana A, Koivukangas J, Ebeling T, Pirilä T (2010) Incidence of pituitary adenomas in northern finland in 1992–2007. J Clin Endocrinol Metab 95:4268–4275. 10.1210/JC.2010-053720534753 10.1210/JC.2010-0537
6. Nilsson B Gustavsson-Kadaka E Bengtsson BÅ Jonsson B Pituitary adenomas in sweden between 1958 and 1991: incidence, survival, and mortality J Clin Endocrinol Metab 2000 85 1420 1425 10.1210/jc.85.4.1420 10770176
Nilsson B, Gustavsson-Kadaka E, Bengtsson BÅ, Jonsson B (2000) Pituitary adenomas in sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 85:1420–1425. 10.1210/jc.85.4.142010770176 10.1210/jc.85.4.1420
7. Bioletto F Berton AM Prencipe N Markers of aggressiveness in pituitary tumors: update and perspectives J Clin Med 2022 11 6508 10.3390/jcm11216508 36362740
Bioletto F, Berton AM, Prencipe N et al (2022) Markers of aggressiveness in pituitary tumors: update and perspectives. J Clin Med 11:6508. 10.3390/jcm1121650836362740 10.3390/jcm11216508
8. Greenman Y Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas Eur J Endocrinol 2017 177 R113 R124 10.1530/EJE-17-0216 28468768
Greenman Y (2017) Management of endocrine disease: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol 177:R113–R124. 10.1530/EJE-17-021628468768 10.1530/EJE-17-0216
9. Dekkers OM Pereira AM Romijn JA Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas J Clin Endocrinol Metab 2008 93 3717 3726 10.1210/jc.2008-0643 18682516
Dekkers OM, Pereira AM, Romijn JA (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 93:3717–3726. 10.1210/jc.2008-064318682516 10.1210/jc.2008-0643
10. Dekkers OM Pereira AM Roelfsema F Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma J Clin Endocrinol Metab 2006 91 1796 1801 10.1210/jc.2005-2552 16507632
Dekkers OM, Pereira AM, Roelfsema F et al (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:1796–1801. 10.1210/jc.2005-255216507632 10.1210/jc.2005-2552
11. Karamouzis I Berardelli R Prencipe N Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas J Endocrinol Invest 2015 38 1191 1197 10.1007/s40618-015-0361-0 26215449
Karamouzis I, Berardelli R, Prencipe N et al (2015) Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas. J Endocrinol Invest 38:1191–1197. 10.1007/s40618-015-0361-026215449 10.1007/s40618-015-0361-0
12. Dekkers OM Hammer S de Keizer RJW The natural course of non-functioning pituitary macroadenomas Eur J Endocrinol 2007 156 217 224 10.1530/eje.1.02334 17287411
Dekkers OM, Hammer S, de Keizer RJW et al (2007) The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 156:217–224. 10.1530/eje.1.0233417287411 10.1530/eje.1.02334
13. Dekkers OM Van Der Klaauw AA Pereira AM Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma J Clin Endocrinol Metab 2006 91 3364 3369 10.1210/jc.2006-0003 16787991
Dekkers OM, Van Der Klaauw AA, Pereira AM et al (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:3364–3369. 10.1210/jc.2006-000316787991 10.1210/jc.2006-0003
14. Ntali G Capatina C Fazal-Sanderson V Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up Eur J Endocrinol 2016 174 137 145 10.1530/EJE-15-0967 26546611
Ntali G, Capatina C, Fazal-Sanderson V et al (2016) Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol 174:137–145. 10.1530/EJE-15-096726546611 10.1530/EJE-15-0967
15. Oh JS Kim HJ Hann HJ Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study Pituitary 2021 24 38 47 10.1007/s11102-020-01084-6 32949324
Oh JS, Kim HJ, Hann HJ et al (2021) Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. Pituitary 24:38–47. 10.1007/s11102-020-01084-632949324 10.1007/s11102-020-01084-6
16. Olsson DS Nilsson AG Bryngelsson IL Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a swedish nationwide study J Clin Endocrinol Metab 2015 100 2651 2658 10.1210/jc.2015-1475 25946030
Olsson DS, Nilsson AG, Bryngelsson IL et al (2015) Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a swedish nationwide study. J Clin Endocrinol Metab 100:2651–2658. 10.1210/jc.2015-147525946030 10.1210/jc.2015-1475
17. Nielsen EH Lindholm J Laurberg P Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function Pituitary 2007 10 67 73 10.1007/s11102-007-0018-x 17356906
Nielsen EH, Lindholm J, Laurberg P et al (2007) Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10:67–73. 10.1007/s11102-007-0018-x17356906 10.1007/s11102-007-0018-x
18. Dekkers O Biermasz N Pereira A Mortality in patients treated for cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma J Clin Endocrinol Metab 2007 92 976 981 10.1210/jc.2006-2112 17200171
Dekkers O, Biermasz N, Pereira A et al (2007) Mortality in patients treated for cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981. 10.1210/jc.2006-211217200171 10.1210/jc.2006-2112
19. Chang EF Zada G Kim S Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas J Neurosurg 2008 108 736 745 10.3171/JNS/2008/108/4/0736 18377253
Chang EF, Zada G, Kim S et al (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108:736–745. 10.3171/JNS/2008/108/4/073618377253 10.3171/JNS/2008/108/4/0736
20. Pappachan JM Raskauskiene D Kutty VR Clayton RN Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies J Clin Endocrinol Metab 2015 100 1405 1411 10.1210/jc.2014-3787 25658016
Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN (2015) Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 100:1405–1411. 10.1210/jc.2014-378725658016 10.1210/jc.2014-3787
21. Van Bunderen CC Van Nieuwpoort IC Arwert LI Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? data from the dutch national registry of growth hormone treatment in adults J Clin Endocrinol Metab 2011 96 3151 3159 10.1210/jc.2011-1215 21849531
Van Bunderen CC, Van Nieuwpoort IC, Arwert LI et al (2011) Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? data from the dutch national registry of growth hormone treatment in adults. J Clin Endocrinol Metab 96:3151–3159. 10.1210/jc.2011-121521849531 10.1210/jc.2011-1215
22. Gaillard RC Mattsson AF Åkerblad AC Overall and cause-specific mortality in GH-deficient adults on GH replacement Eur J Endocrinol 2012 166 1069 1077 10.1530/EJE-11-1028 22457236
Gaillard RC, Mattsson AF, Åkerblad AC et al (2012) Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 166:1069–1077. 10.1530/EJE-11-102822457236 10.1530/EJE-11-1028
23. Svensson J Bengtsson BÅ Rosén T Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy J Clin Endocrinol Metab 2004 89 3306 3312 10.1210/jc.2003-031601 15240607
Svensson J, Bengtsson BÅ, Rosén T et al (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306–3312. 10.1210/jc.2003-03160115240607 10.1210/jc.2003-031601
24. Tomlinson JW Holden N Hills RK Association between premature mortality and hypopituitarism Lancet 2001 357 425 431 10.1016/S0140-6736(00)04006-X 11273062
Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. Lancet 357:425–431. 10.1016/S0140-6736(00)04006-X11273062 10.1016/S0140-6736(00)04006-X
25. Nielsen EH Lindholm J Laurberg P Excess mortality in women with pituitary disease: a meta-analysis Clin Endocrinol (Oxf) 2007 67 693 697 10.1111/j.1365-2265.2007.02947.x 17634076
Nielsen EH, Lindholm J, Laurberg P (2007) Excess mortality in women with pituitary disease: a meta-analysis. Clin Endocrinol (Oxf) 67:693–697. 10.1111/j.1365-2265.2007.02947.x17634076 10.1111/j.1365-2265.2007.02947.x
26. Sherlock M Ayuk J Tomlinson JW Mortality in patients with pituitary disease Endocr Rev 2010 31 301 342 10.1210/er.2009-0033 20086217
Sherlock M, Ayuk J, Tomlinson JW et al (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301–342. 10.1210/er.2009-003320086217 10.1210/er.2009-0033
27. Hsiao PK Chang CL Yuan KSP Results of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, and transsphenoidal surgery in nonfunctioning pituitary macroadenoma J Clin Med 2019 10.3390/jcm8040518 31703305
Hsiao PK, Chang CL, Yuan KSP et al (2019) Results of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, and transsphenoidal surgery in nonfunctioning pituitary macroadenoma. J Clin Med. 10.3390/jcm804051831703305 10.3390/jcm8040518
28. Rim CH Yang DS Park YJ Radiotherapy for pituitary adenomas: long-term outcome and complications Radiat Oncol J 2011 29 156 10.3857/roj.2011.29.3.156 22984666
Rim CH, Yang DS, Park YJ et al (2011) Radiotherapy for pituitary adenomas: long-term outcome and complications. Radiat Oncol J 29:156. 10.3857/roj.2011.29.3.15622984666 10.3857/roj.2011.29.3.156
29. Moher D, Liberati A, Tetzlaff J, et al (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e1000097. 10.1371/journal.pmed.1000097
30. Wells G, Shea B, O’Connell D, et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 8 Aug 2023
31. Vandenbroucke J A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio Am J Epidemiol 1982 115 303 304 10.1093/oxfordjournals.aje.a113306
Vandenbroucke J (1982) A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio. Am J Epidemiol 115:303–30410.1093/oxfordjournals.aje.a113306
32. Lindholm J Nielsen EH Bjerre P Hypopituitarism and mortality in pituitary adenoma Clin Endocrinol (Oxf) 2006 65 51 58 10.1111/j.1365-2265.2006.02545.x 16817819
Lindholm J, Nielsen EH, Bjerre P et al (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf) 65:51–58. 10.1111/j.1365-2265.2006.02545.x16817819 10.1111/j.1365-2265.2006.02545.x
33. O’Reilly MW Reulen RC Gupta S ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centres Clin Endocrinol (Oxf) 2016 85 748 756 10.1111/cen.13141 27327840
O’Reilly MW, Reulen RC, Gupta S et al (2016) ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centres. Clin Endocrinol (Oxf) 85:748–756. 10.1111/cen.1314127327840 10.1111/cen.13141
34. Hammarstrand C Ragnarsson O Hallén T Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma Eur J Endocrinol 2017 177 251 256 10.1530/EJE-17-0340 28596421
Hammarstrand C, Ragnarsson O, Hallén T et al (2017) Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol 177:251–256. 10.1530/EJE-17-034028596421 10.1530/EJE-17-0340
35. Olsson DS Trimpou P Hallén T Life expectancy in patients with pituitary adenoma receiving growth hormone replacement Eur J Endocrinol 2017 176 67 75 10.1530/EJE-16-0450 27770012
Olsson DS, Trimpou P, Hallén T et al (2017) Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. Eur J Endocrinol 176:67–75. 10.1530/EJE-16-045027770012 10.1530/EJE-16-0450
36. Sherlock M Reulen RC Alonso AA ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly J Clin Endocrinol Metab 2009 94 4216 4223 10.1210/jc.2009-1097 19808848
Sherlock M, Reulen RC, Alonso AA et al (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223. 10.1210/jc.2009-109719808848 10.1210/jc.2009-1097
37. Filipsson H Monson JP Koltowska-Häggström M The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients J Clin Endocrinol Metab 2006 91 3954 3961 10.1210/jc.2006-0524 16895963
Filipsson H, Monson JP, Koltowska-Häggström M et al (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961. 10.1210/jc.2006-052416895963 10.1210/jc.2006-0524
38. Appelman-Dijkstra NM Claessen KMJA Roelfsema F Long-term effects of recombinant human GH replacement in adults with GH deficiency: A systematic review Eur J Endocrinol 2013 169 1 R1 4 10.1530/EJE-12-1088 23572082
Appelman-Dijkstra NM, Claessen KMJA, Roelfsema F et al (2013) Long-term effects of recombinant human GH replacement in adults with GH deficiency: A systematic review. Eur J Endocrinol 169(1):R1-423572082 10.1530/EJE-12-1088
39. Johannsson G Bergthorsdottir R Nilsson AG Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study Eur J Endocrinol 2009 161 119 130 10.1530/EJE-09-0170 19383806
Johannsson G, Bergthorsdottir R, Nilsson AG et al (2009) Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161:119–130. 10.1530/EJE-09-017019383806 10.1530/EJE-09-0170
40. Johannsson G Nilsson AG Bergthorsdottir R Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation J Clin Endocrinol Metab 2012 97 473 481 10.1210/JC.2011-1926 22112807
Johannsson G, Nilsson AG, Bergthorsdottir R et al (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473–481. 10.1210/JC.2011-192622112807 10.1210/JC.2011-1926
41. Debono M Ross RJ Newell-Price J Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy Eur J Endocrinol 2009 160 719 729 10.1530/EJE-08-0874 19168600
Debono M, Ross RJ, Newell-Price J (2009) Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 160:719–729. 10.1530/EJE-08-087419168600 10.1530/EJE-08-0874
42. Molitch ME Clemmons DR Malozowski S Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline J Clin Endocrinol Metab 2011 96 1587 1609 10.1210/jc.2011-0179 21602453
Molitch ME, Clemmons DR, Malozowski S et al (2011) Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1587–160921602453 10.1210/jc.2011-0179
43. Casanueva FF Castro AI Micic D New guidelines for the diagnosis of growth hormone deficiency in adults Horm Res 2009 71 112 115 10.1159/000178051 19153519
Casanueva FF, Castro AI, Micic D et al (2009) New guidelines for the diagnosis of growth hormone deficiency in adults. Horm Res 71:112–115. 10.1159/00017805119153519 10.1159/000178051
44. Fleseriu M Hashim IA Karavitaki N Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline J Clin Endocrinol Metab 2016 101 3888 3921 10.1210/jc.2016-2118 27736313
Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–392127736313 10.1210/jc.2016-2118
45. Andersen S Pedersen KM Bruun NH Laurberg P Narrow individual variations in serum T4 and T3 in normal subjects: A clue to the understanding of subclinical thyroid disease J Clin Endocrinol Metab 2002 87 1068 1072 10.1210/jcem.87.3.8165 11889165
Andersen S, Pedersen KM, Bruun NH, Laurberg P (2002) Narrow individual variations in serum T4 and T3 in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87:1068–1072. 10.1210/jcem.87.3.816511889165 10.1210/jcem.87.3.8165
